References
- NCI. SEER Cancer Stat Fact Sheets. Bethesda, MD: National Cancer Institute. 2014.
- Freedland SJ. Obesity and prostate cancer: a growing problem. Clin Cancer Res. 2005;11(19 Pt 1):6763–6. doi:https://doi.org/10.1158/1078-0432.CCR-05-1305
- Miller DC, Hafez KS, Stewart A, Montie JE, Wei JT. Prostate carcinoma presentation, diagnosis, and staging: an update form the National Cancer Data Base. Cancer. 2003;98(6):1169–78. doi:https://doi.org/10.1002/cncr.11635
- Daryabor G, Kabelitz D, Kalantar K. An update on immune dysregulation in obesity-related insulin resistance. Scand J Immunol. 2019;89(4):e12747. doi:https://doi.org/10.1111/sji.12747
- Finley DS, Calvert VS, Inokuchi J, Lau A, Narula N, Petricoin EF, Zaldivar F, Santos R, Tyson DR, Ornstein DK. Periprostatic adipose tissue as a modulator of prostate cancer agressiveness. J Urol. 2009;182(4):1621–7. doi:https://doi.org/10.1016/j.juro.2009.06.015
- Tartour E, Fossiez F, Joyeux I, Galinha A, Gey A, Claret E, Sastre-Garau X, Couturier J, Mosseri V, Vives V, et al. Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. Cancer Res. 1999;59(15):3698–704.
- Lou W, Ni Z, Dyer K, Tweardy DJ, Gao AC. Interleukin-6 induces prostate cancer cell growth accompanied by activation of Stat3 signaling pathway. Prostate. 2000;42(3):239–42. doi:https://doi.org/10.1002/(SICI)1097-0045(20000215)42:3<239::AID-PROS10>3.0.CO;2-G
- Lee SO, Chun JY, Nadiminty N, Lou W, Gao AC. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression. Prostate. 2007;67(7):764–73. doi:https://doi.org/10.1002/pros.20553
- You Z. Interleukin-17 induces expression of chemokines and cytokines in prostatic epithelial cells but does not stimulate cell growth in vitro. Int J Med Biol Front. 2012;18(8):629–44.
- Steiner GE, Newman ME, Paikl D, Stix U, Memaran-Dagda N, Lee C, Marberger MJ. Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate. Prostate. 2003;56(3):171–82. doi:https://doi.org/10.1002/pros.10238
- Numasaki M, Fukushi J-i, Ono M, Narula SK, Zavodny PJ, Kudo T, Robbins PD, Tahara H, Lotze MT. Interleukin-17 promotes angiogenesis and tumor growth. Blood. 2003;101(7):2620–7. doi:https://doi.org/10.1182/blood-2002-05-1461
- Zhang Q, Liu S, Zhang Q, Xiong Z, Wang AR, Myers L, Melamed J, Tang WW, You Z. Interleukin-17 promotes development of castration-resistant prostate cancer potentially through creating an immunotolerant and pro-angiogenic tumor microenvironment. Prostate. 2014;74(8):869–79. doi:https://doi.org/10.1002/pros.22805
- Adler HL, McCurdy MA, Kattan MW, Timme TL, Scardino PT, Thompson TC. Elevated levels of circulating interleukin-6 and transforming growth factor-beta 1 in patients with metastatic prostatic carcinoma. J Urol. 1999;161(1):182–7. doi:https://doi.org/10.1016/S0022-5347(01)62092-5
- Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, Darnell JE. Stat3 as an oncogene. Cell. 1999;98(3):295–303. doi:https://doi.org/10.1016/S0092-8674(00)81959-5
- Azare J, Leslie K, Al-Ahmadie H, Gerald W, Weinreb PH, Violette SM, Bromberg J. Constitutively activated Stat3 induces tumorigenesis and enhances cell motility of prostate epithelial cells through integrin beta 6. Mol Cell Biol. 2007;27(12):4444–53. doi:https://doi.org/10.1128/MCB.02404-06
- Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009;9(11):798–809. doi:https://doi.org/10.1038/nrc2734
- Thiery JP, Acloque H, Huang RYJ, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139(5):871–90. doi:https://doi.org/10.1016/j.cell.2009.11.007
- Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009;119(6):1420–8. doi:https://doi.org/10.1172/JCI39104
- Zeisberg M, Neilson EG. Biomarkers for epithelial-mesenchymal transitions. J Clin Invest. 2009;119(6):1429–37. doi:https://doi.org/10.1172/JCI36183
- Sanchez-Tillo E, et al. EMT-activating transcription factors in cancer: beyond EMT and tumor invasiveness. Cell Mol Life Sci. 2012;69(20):3429–56.
- Cerqueira MA, Ferrari KL, de Mattos AC, Monti CR, Reis LO. T cells CD4+/CD8+ local immune modulation by prostate cancer hemi-cryoablation. World J Urol. 2019;38(3):673–80. doi:https://doi.org/10.1007/s00345-019-02861-0
- Fujita K, Hayashi T, Matsushita M, Uemura M, Nonomura N. Obesity, inflammation, and prostate cancer. JCM. 2019;8(2):201. doi:https://doi.org/10.3390/jcm8020201
- Qu X, Tang Y, Hua S. Immunological approaches towards cancer and inflammation: a cross talk. Front Immunol. 2018;9:563. doi:https://doi.org/10.3389/fimmu.2018.00563
- Wang Z, Aguilar EG, Luna JI, Dunai C, Khuat LT, Le CT, Mirsoian A, Minnar CM, Stoffel KM, Sturgill IR, et al. Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade. Nat Med. 2019;25(1):141–151. doi:https://doi.org/10.1038/s41591-018-0221-5
- Shirakawa K, Yan X, Shinmura K, Endo J, Kataoka M, Katsumata Y, Yamamoto T, Anzai A, Isobe S, Yoshida N, et al. Obesity accelerates T cell senescence in murine visceral adipose tissue. J Clin Invest. 2016;126(12):4626–4639. doi:https://doi.org/10.1172/JCI88606
- Galvan GC, et al. Effects of obesity on the regulation of macrophage population in the prostate tumor microenvironment. Nutr Cancer. 2017;69(7):996–1002.
- Zhang J, Sadowska GB, Chen X, Park SY, Kim J‐E, Bodge CA, Cummings E, Lim Y‐P, Makeyev O, Besio WG, et al. Anti-IL-6 neutralizing antibody modulates blood-brain barrier function in the ovine fetus. FASEB J. 2015;29(5):1739–53. doi:https://doi.org/10.1096/fj.14-258822
- Li Z, Zhang C, Du J-X, Zhao J, Shi M-T, Jin M-W, Liu H. Adipocytes promote tumor progression and induce PD-L1 expression via TNF-α/IL-6 signaling. Cancer Cell Int. 2020;20:179. doi:https://doi.org/10.1186/s12935-020-01269-w
- Gc G, et al. Effects of obesity on the regulation of macrophage population in the prostate tumor microenvironment. Nutr Cancer. 2017:69(7):996-1002. doi:https://doi.org/10.1080/01635581.2017.1359320
- Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell. 2008;14(6):818–29. doi:https://doi.org/10.1016/j.devcel.2008.05.009
- Batlle E, Sancho E, Francí C, Domínguez D, Monfar M, Baulida J, García De Herreros A. The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol. 2000;2(2):84–9. doi:https://doi.org/10.1038/35000034
- Karreth F, Tuveson DA. Twist induces an epithelial-mesenchymal transition to facilitate tumor metastasis. Cancer Biol Ther. 2004;3(11):1058–9. doi:https://doi.org/10.4161/cbt.3.11.1302
- Li X, Yang J, Wang X, Li X, Liang J, Xing H. Role of TWIST2, E-cadherin and Vimentin in epithelial ovarian carcinogenesis and prognosis and their interaction in cancer progression. Eur J Gynaecol Oncol. 2016;37(1):100–8.
- Richardson AM, Havel LS, Koyen AE, Konen JM, Shupe J, Wiles WG, Martin WD, Grossniklaus HE, Sica G, Gilbert-Ross M, et al. Vimentin is required for lung adenocarcinoma metastasis via heterotypic tumor cell-cancer-associated fibroblast interactions during collective invasion. Clin Cancer Res. 2018;24(2):420–432. doi:https://doi.org/10.1158/1078-0432.CCR-17-1776
- Steinbichler TB, et al. Pleiotropic effects of epithelial mesenchymal crosstalk on head and neck cancer: EMT and beyond. Cancer Microenviron. 2019;12;67–76. doi:https://doi.org/10.1007/s12307-019-00228-y
- Agrez M, Chen A, Cone RI, Pytela R, Sheppard D. The alpha v beta 6 integrin promotes proliferation of colon carcinoma cells through a unique region of the beta 6 cytoplasmic domain. J Cell Biol. 1994;127(2):547–56. doi:https://doi.org/10.1083/jcb.127.2.547
- Kumra H, Reinhardt DP. Fibronectin-targeted drug delivery in cancer. Adv Drug Deliv Rev. 2016;97:101–10. doi:https://doi.org/10.1016/j.addr.2015.11.014
- Gopal S, Veracini L, Grall D, Butori C, Schaub S, Audebert S, Camoin L, Baudelet E, Radwanska A, Beghelli-de la Forest Divonne S, et al. Fibronectin-guided migration of carcinoma collectives. Nat Commun. 2017;8:14105. doi:https://doi.org/10.1038/ncomms14105
- Gloeckler Ries LA, Reichman ME, Lewis DR, Hankey BF, Edwards BK. Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist. 2003;8(6):541–52. doi:https://doi.org/10.1634/theoncologist.8-6-541
- Allott EH, Masko EM, Freedland SJ. Obesity and prostate cancer: weighing the evidence. Eur Urol. 2013;63(5):800–9. doi:https://doi.org/10.1016/j.eururo.2012.11.013
- Park EJ, Lee JH, Yu G-Y, He G, Ali SR, Holzer RG, Osterreicher CH, Takahashi H, Karin M. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell. 2010;140(2):197–208. doi:https://doi.org/10.1016/j.cell.2009.12.052
- Johnson AR, Milner JJ, Makowski L. The inflammation highway: metabolism accelerates inflammatory traffic in obesity. Immunol Rev. 2012;249(1):218–38. doi:https://doi.org/10.1111/j.1600-065X.2012.01151.x
- Wu H, Ballantyne CM. Inflammation versus host defense in obesity. Cell Metab. 2014;20(5):708–709. doi:https://doi.org/10.1016/j.cmet.2014.10.013
- Gainsford T, Willson TA, Metcalf D, Handman E, McFarlane C, Ng A, Nicola NA, Alexander WS, Hilton DJ. Leptin can induce proliferation, differentiation, and functional activation of hemopoietic cells. Proc Natl Acad Sci U S A. 1996;93(25):14564–8. doi:https://doi.org/10.1073/pnas.93.25.14564
- Cohen S, Danzaki K, MacIver NJ. Nutritional effects on T-cell immunometabolism. Eur J Immunol. 2017;47(2):225–235. doi:https://doi.org/10.1002/eji.201646423
- Kim H, Kim H-S, Youn J-C, Shin E-C, Park S. Serum cytokine profiles in healthy young and elderly population assessed using multiplexed bead-based immunoassays. J Transl Med. 2011;9(1):113. doi:https://doi.org/10.1186/1479-5876-9-113
- Tabassum DP, Polyak K. Tumorigenesis: it takes a village. Nat Rev Cancer. 2015;15(8):473–83. doi:https://doi.org/10.1038/nrc3971
- Li Q, Liu L, Zhang Q, Liu S, Ge D, You Z. Interleukin-17 indirectly promotes M2 macrophage differentiation through stimulation of COX-2/PGE2 pathway in the cancer cells. Cancer Res Treat. 2014;46(3):297–306. doi:https://doi.org/10.4143/crt.2014.46.3.297
- Teeling EC, Springer MS, Madsen O, Bates P, O’brien SJ, Murphy WJ. A molecular phylogeny for bats illuminates biogeography and the fossil record. Science. 2005;307(5709):580–584. doi:https://doi.org/10.1126/science.1105113
- Wu S-Q, Su H, Wang Y-H, Zhao X-K. Role of tumor-associated immune cells in prostate cancer: angel or devil? Asian J Androl. 2019;21(5):433–437. doi:https://doi.org/10.4103/aja.aja_47_19
- Vitkin N, Nersesian S, Siemens DR, Koti M. The tumor immune contexture of prostate cancer. Front Immunol. 2019;10:603. doi:https://doi.org/10.3389/fimmu.2019.00603